Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CollPlant Biotechnologies (CLGN) EBITDA Margin (2017 - 2025)

CollPlant Biotechnologies filings provide 9 years of EBITDA Margin readings, the most recent being 5250.0% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 282683.0% to 5250.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 77.22%, a 11975.0% decrease, with the full-year FY2025 number at 484.31%, up 286540.0% from a year prior.
  • EBITDA Margin hit 5250.0% in Q4 2025 for CollPlant Biotechnologies, down from 4554.55% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 4417.35% in Q1 2024 to a low of 113550.0% in Q3 2024.
  • Median EBITDA Margin over the past 5 years was 1227.1% (2021), compared with a mean of 7414.48%.
  • Biggest five-year swings in EBITDA Margin: tumbled -11354999bps in 2024 and later soared 10899545bps in 2025.
  • CollPlant Biotechnologies' EBITDA Margin stood at 1227.1% in 2021, then crashed by -557bps to 8062.07% in 2022, then skyrocketed by 79bps to 1694.98% in 2023, then crashed by -43bps to 2423.17% in 2024, then plummeted by -117bps to 5250.0% in 2025.
  • The last three reported values for EBITDA Margin were 5250.0% (Q4 2025), 4554.55% (Q3 2025), and 1775.42% (Q2 2025) per Business Quant data.